Aqueous cytokines as predictors of the recurrence of macular edema after Anti-Vascular-Endothelial Growth Factor therapy in retinal vein occlusion.

Aqueous cytokines as predictors of the recurrence of macular edema after Anti-Vascular-Endothelial Growth Factor therapy in retinal vein occlusion. - Aqueous cytokines as predictors of the recurrence of macular edema in retinal vein occlusion

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022712

Enrollment

Registered

2016-06-13

Start date

2016-06-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal vein occlusion

Interventions

Administration of Anti-Vascular Endothelial Growth Factor until improvement in macular edema

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with macular edema due to retinal vein occlusion in phakic or pseudophakic eyes Patients who agree in writing to participate in this study after enough explanation

Exclusion criteria

Exclusion criteria: Patients who are going to undergo other intraocular surgery

Design outcomes

Primary

Measure	Time frame
The concentration of VEGF, IL-1Beta, IL-6, IL-8, TGF-Beta, bFGF and SAA in the aqueous humor	—

Secondary

Measure	Time frame
Central macular thickness, Flare	—

Countries

Japan

Contacts

Public ContactMakoto Gozawa

University of Fukui, Faculty of Medical Sciences Department of Ophthalmology

makoto.gozawa@gmail.com0776618403

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026